iiinova — where your digital self keeps evolving

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

Overall, we isolated 5 neutralising mAbs against NL63, 4 against the RBD and 1 against the S2 stalk. The S2 mAb had unusually high neutralising potency comparable to RBD mAbs, and targeted a region that is extended in α-CoVs, potentially revealing a site of vulnerability absent in β-CoVs.

000

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

Interestingly, while NL63 was able to escape these neutralising mAbs in vitro, these escape mutations were not found in over 207 sequences spanning 1983-2023, matching previous data indicating that NL63 does not undergo adaptive evolution unlike HCoV OC43 and 229E (elifesciences.org/articles/64509).

100

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

The escape mutations for the non-RBD neutralising mAb (NLH02) were located within the membrane proximal HR2 region of the S2 subunit (within the stalk of spike), suggesting a neutralisation mechanism that interferes with viral fusion as described previously for S2 mAbs against SARS-CoV-2.

110

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

To further map where these mAbs bind to on spike, we generated escape variants to each of the neutralising mAbs. Escape mutations for the RBD neutralising mAbs were concentrated on the three discontinuous receptor binding motif loops of RBD.

100

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

4 of the 5 neutralising mAbs were specific for the receptor binding domain (RBD: Domain S1B) and could inhibit the RBD from binding to its receptor ACE2

100

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

We isolated 9 monoclonal antibodies against the entry protein (spike) of NL63, 5 of which had neutralising activity against the prototypic Amsterdam-1 isolate and other contemporary NL63 isolates that we cultured from PCR+ nasal swabs. Binding and neutralising IC50 values summarised below:

100

ViralVax Lab @viralvaxlab.bsky.social · 01/05/2025

We are excited to share our paper describing neutralising monoclonal antibodies against human coronavirus NL63, an alphacoronavirus that uses the same ACE2 receptor as SARS-CoV and SARS-CoV-2, but generally only causes mild respiratory illness. www.nature.com/articles/s44...

nature.com

Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus - npj Viruses

npj Viruses - Potent neutralising monoclonal antibodies targeting the spike of NL63 coronavirus

152

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

5/ Settling the #LeftvsRight debate: Ipsilateral prime-boost could be an optimal strategy for rapidly maximising humoral immunity during early outbreak phases, with particular relevance for vaccine strategies requiring multidose schedules.

100

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

4/ In our heterologous WT/BA.1 prime-boost model, we observed differential recognition patterns in cross-reactive GC B cells depending on vaccination site. Same-arm boosting also provided a transient advantage in breadth against the BA.1 spike variant.

100

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

3/ Alternate side vaccination established independent GCs at distinct lymph nodes. Interestingly, by day 28, antibody levels between both vaccination approaches became comparable in magnitude, durability, and neutralisation capacity.

100

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

2/ We found that same side vaccination accelerated antibody production, with significantly higher titers at day 19, coupled with sustained GCs in the primary draining lymph nodes.

100

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

1/ Hot off the press in @jimmunol.bsky.social. We investigated how same side (ipsilateral) vs alternate side (contralateral) prime-boost vaccination impacts germinal center (GC) dynamics & antibody responses against SARS-CoV-2 spike in mice.💉🦠#immunology #vaccines @thedohertyinst.bsky.social

133

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

000

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

100

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

100

ViralVax Lab @viralvaxlab.bsky.social · 11/03/2025

2/ We found that same side vaccination accelerated antibody production, with significantly higher titers at day 19, coupled with sustained GCs in the primary draining lymph nodes.

100

ViralVax Lab @viralvaxlab.bsky.social · 10/01/2025

Check out the latest from @skentskent.bsky.social and team - how does co-administration of influenza and COVID-19 vaccines affect immunity? Congrats to Wen Shi Lee, Kevin Selva and Jen Audsley on a great study and collaboration between the ViralVax and Chung labs! insight.jci.org/articles/vie...

010